Korro Bio's RNA Editing Drug Shows Promise but Falls Short of Efficacy Targets in Alpha-1 Antitrypsin Deficiency Trial
核心洞察
Korro Bio's KRRO-110 successfully produced functional M-AAT protein (搜索) in Alpha-1 Antitrypsin Deficiency (搜索) patients but failed to reach the protective threshold of 11 µM needed for therapeutic benefit.
The company is pivoting to a GalNAc-conjugated delivery system for AATD (搜索) treatment, with development candidate nomination expected in the first half of 2026.
Korro nominated KRRO-121 (搜索), a new RNA editing candidate targeting hyperammonemia (搜索) in urea cycle disorders (搜索) and hepatic encephalopathy (搜索) patients.
Korro Bio announced mixed results from its Phase 1/2a REWRITE clinical trial of KRRO-110 in Alpha-1 Antitrypsin Deficiency (搜索) (AATD (搜索)), demonstrating proof-of-concept for RNA editing in humans while revealing efficacy limitations that have prompted a strategic pivot to alternative delivery approaches.
The Cambridge-based biotech reported that KRRO-110 successfully generated functional M-AAT protein (搜索) in AATD (搜索) patients, marking the first clinical validation of the company's RNA editing platform. However, the treatment failed to achieve projected protein levels, with total AAT protein reaching only approximately 10 µM compared to the protective threshold of 11 µM required for therapeutic benefit.
Clinical Trial Results Reveal Platform Potential and Limitations
In the REWRITE study, KRRO-110 was evaluated across six single ascending dose cohorts in healthy volunteers (0.04 to 1.2 mg/kg) and two patient cohorts at 0.6 mg/kg and 0.8 mg/kg. Among seven AATD (搜索) patients dosed, functional M-AAT protein (搜索) was observed in all three patients evaluable at the 0.8 mg/kg dose level using LC/MS analysis.
The greatest increase of M-AAT protein (搜索) from baseline was approximately 2 µM, with functional protein persisting up to four weeks in the first evaluable patient. This duration aligns with the endogenous M-AAT protein half-life, suggesting successful RNA editing durability.
"We're encouraged by the evidence of clinical activity, which we believe confirms our ability to edit RNA and produce therapeutic proteins in humans," said Ram Aiyar, Ph.D., CEO and President of Korro Bio. "While a single administration of KRRO-110 achieved functional protein production, it did not achieve the protein levels we projected based on preclinical data."
Pharmacokinetic Differences Drive Strategic Pivot
Initial analysis revealed pharmacokinetic differences in KRRO-110 components between healthy volunteers and AATD (搜索) patients, with apparent faster disassociation of the drug in patient populations. This variability in the lipid nanoparticle formulation contributed to the suboptimal protein levels observed.
The safety profile remained manageable, with no dose-limiting toxicities or serious adverse events reported. Mild-to-moderate infusion-related reactions occurred in six participants across dose levels but resolved within 24 hours with standard interventions.
Based on these insights, Korro is pivoting to a GalNAc-conjugated construct for AATD (搜索) treatment, leveraging improved potency developments. The company expects to nominate a development candidate for this approach in the first half of 2026.
Pipeline Expansion with KRRO-121 for Hyperammonemia
Korro nominated KRRO-121 (搜索) as its next development candidate, targeting hyperammonemia (搜索) in patients with urea cycle disorders (搜索) (UCD) and hepatic encephalopathy (搜索) (HE). This GalNAc-conjugated oligonucleotide represents the company's first expansion beyond protein repair, designed to create a de novo protein variant that activates biological pathways for ammonia reduction.
KRRO-121 (搜索) is intended to treat all UCD patients regardless of mutational background, representing a pan-UCD approach. For hepatic encephalopathy (搜索) patients, the treatment aims to prevent or reduce hyperammonemic crises. The subcutaneous administration route offers potential advantages over current treatment modalities.
Regulatory filing to enable first-in-human trials for KRRO-121 (搜索) is anticipated in the second half of 2026, with the GalNAc version for AATD (搜索) patients expected to enter clinical development in 2027.
Strategic Restructuring Extends Operational Runway
To focus resources on liver-targeted GalNAc programs, Korro implemented a strategic restructuring reducing its workforce by approximately 34%. The company estimates one-time restructuring charges of approximately $2.4 million, primarily recognized in the fourth quarter of 2025.
The restructuring extends Korro's cash runway into the second half of 2027, with $102.5 million in cash, cash equivalents, and marketable securities as of September 30, 2025. This provides sufficient capital to deliver clinical data from KRRO-121 (搜索) and advance at least one additional program.
Regulatory Validation Supports Platform Potential
Despite the efficacy challenges, KRRO-110 achieved significant regulatory milestones that validate the OPERA platform's potential. The treatment became the first RNA editing technology to receive Investigational New Drug clearance from the FDA, along with Fast Track designation and Orphan Drug Designation from both FDA and European Medicines Agency.
The clinical data demonstrated high specificity with no evidence of bystander editing observed, supporting the precision of Korro's RNA editing approach. This specificity, combined with the transient nature of RNA editing compared to DNA modification, positions the platform for continued development across multiple indications.
Korro also amended its research collaboration with Novo Nordisk, establishing a 12-month pause to reassess the current target rationale under their first research program, while maintaining the broader partnership framework for future opportunities.